Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory acute myeloid leukemia (AML).
Robert Collins
No relevant relationships to disclose
Hagop M. Kantarjian
No relevant relationships to disclose
Mark J. Levis
No relevant relationships to disclose
Alexander E. Perl
Consultant or Advisory Role - Ambit BioSciences (U); Arog (U); Astellas Pharma (U)
Abhijit Ramachandran
Employment or Leadership Position - Arog
Farhad Ravandi
No relevant relationships to disclose
Nora Ku
Employment or Leadership Position - Arog
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Astellas Pharma; Novartis
Research Funding - Ambit BioSciences; ARIAD; Arog; Astellas Pharma; Cell Therapeutics; Novartis